Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach

被引:153
作者
Obach, RS [1 ]
Reed-Hagen, AE [1 ]
机构
[1] Pfizer Global Res & Dev, Pharmacokinet Pharmacodynam & Drug Metab, Groton, CT USA
关键词
D O I
10.1124/dmd.30.7.831
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Michaelis constant (K-M) for cytochrome P450-mediated drug biotransformation reactions can be an important parameter in understanding the potential for a drug to exhibit saturable metabolism in vivo and nonlinear dose-exposure relationships. K-M values were measured for several drug biotransformation reactions using recombinant heterologously expressed human enzymes. These determinations were made using an approach of monitoring substrate loss ("in vitro t(1/2)" method) at multiple substrate concentrations, with the objective of comparing K-M values determined by this approach with K-M values determined using the conventional approach of measuring product formation rates at several substrate concentrations. The reactions examined were CYP2C9-catalyzed diclofenac 4'-hydroxylation, CYP2D6-catalyzed dextromethorphan O-demethylation and thioridazine S-oxidation, CYP2C19-catalyzed imipramine N-demethylation, CYP3A4-catalyzed midazolam 1'-hydroxylation, and CYP1A2-catalyzed tacrine 1-hydroxylation. K-M values spanned an 80-fold range from 0.12 muM (CYP2D6-catalyzed thioridazine S-oxidation) to 9.8 muM (CYP2C19-catalyzed imipramine N-demethylation). On average, K-M values determined by the substrate depletion approach were within 1.54-fold of those determined by measuring product formation. Thus, K-M values can be determined for drug metabolism reactions without requiring knowledge of metabolite structures or requiring authentic standards of metabolites for use in construction of standard curves for quantitative bioanalysis. The in vitro t(1/2) approach of determining K-M values should be useful in early drug discovery efforts to identify those compounds with low K-M values and, hence, a greater probability of exhibiting supraproportional dose-exposure relationships.
引用
收藏
页码:831 / 837
页数:7
相关论文
共 26 条
[1]   SINGLE DOSE KINETICS OF THIORIDAZINE AND ITS 2 PSYCHOACTIVE METABOLITES IN HEALTHY HUMANS - A DOSE PROPORTIONALITY STUDY [J].
CHAKRABORTY, BS ;
MIDHA, KK ;
MCKAY, G ;
HAWES, EM ;
HUBBARD, JW ;
KORCHINSKI, ED ;
CHOC, MG ;
ROBINSON, WT .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (10) :796-801
[2]  
Chen TL, 1997, DRUG METAB DISPOS, V25, P544
[3]  
CHRISTOPHERSON PA, 1995, ISSX P, V8, P358
[4]   Non-linear pharmacokinetics of MDMA ('ecstasy') in humans [J].
de la Torre, R ;
Farré, M ;
Ortuño, J ;
Mas, M ;
Brenneisen, R ;
Roset, PN ;
Segura, J ;
Camí, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (02) :104-109
[5]   Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies [J].
Hidalgo, M ;
Villalona-Calero, MA ;
Eckhardt, SG ;
Drengler, RL ;
Rodriguez, G ;
Hammond, LA ;
Diab, SG ;
Weiss, G ;
Garner, AM ;
Campbell, E ;
Davidson, K ;
Louie, A ;
O'Neil, JD ;
von Borstel, R ;
Von Hoff, DD ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :167-177
[6]   Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices [J].
Houston, JB ;
Carlile, DJ .
DRUG METABOLISM REVIEWS, 1997, 29 (04) :891-922
[7]  
Iwatsubo T, 1996, BIOPHARM DRUG DISPOS, V17, P273, DOI 10.1002/(SICI)1099-081X(199605)17:4<273::AID-BDD961>3.0.CO
[8]  
2-R
[9]  
Kalvass JC, 2001, DRUG METAB DISPOS, V29, P1332
[10]   NONLINEAR PHARMACOKINETICS OF NEFAZODONE AFTER ESCALATING SINGLE AND MULTIPLE ORAL DOSES [J].
KAUL, S ;
SHUKLA, UA ;
BARBHAIYA, RH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (08) :830-839